Current Environment: Production

Medical Services

Specialties

Programs & Services

Education

Medical School

Monash University Medical School

Melbourne, Australia

Residency

Pediatrics

Royal Children's Hospital

2005, Melbourne, Australia

Fellowship

Pediatric Hematology-Oncology

Royal Children's Hospital

2009, Melbourne, Australia

Fellowship

Pediatric Neuro-Oncology

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

2013, Boston, MA

Publications

  1. Recurrent breakpoints in the BRD4 locus reduce toxicity associated with gene amplification. Cell Genom. 2025 Apr 09; 5(4):100815. View Abstract

  2. Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025 Apr 14; 43(4):740-756.e8. View Abstract

  3. N-terminal modification of Histone H3 inhibits H3K27M-mediated loss of H3K27 trimethylation. bioRxiv. 2025 Jan 27. View Abstract

  4. A compendium of Amplification-Related Gain Of Sensitivity genes in human cancer. Nat Commun. 2025 Jan 27; 16(1):1077. View Abstract

  5. FOXR2 Targets LHX6+/DLX+ Neural Lineages to Drive Central Nervous System Neuroblastoma. Cancer Res. 2025 Jan 15; 85(2):231-250. View Abstract

  6. Multimodal deep learning improves recurrence risk prediction in pediatric low-grade gliomas. Neuro Oncol. 2025 Jan 12; 27(1):277-290. View Abstract

  7. Pediatric neuro-oncology: Highlights of the last quarter-century. Neoplasia. 2025 Jan; 59:101098. View Abstract

  8. A foundation model for generalized brain MRI analysis. medRxiv. 2024 Dec 03. View Abstract

  9. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Aug 22; 15(1):7218. View Abstract

  10. Genome-wide CRISPR-Cas9 knockout screens identify DNMT1 as a druggable dependency in sonic hedgehog medulloblastoma. Acta Neuropathol Commun. 2024 Aug 07; 12(1):125. View Abstract

  11. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition. Neuro Oncol. 2024 08 05; 26(8):1357-1366. View Abstract

  12. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer. Nat Commun. 2024 Jul 11; 15(1):5837. View Abstract

  13. Longitudinal risk prediction for pediatric glioma with temporal deep learning. medRxiv. 2024 Jun 28. View Abstract

  14. Unraveling the complexity of the senescence-associated secretory phenotype in adamantinomatous craniopharyngioma using multimodal machine learning analysis. Neuro Oncol. 2024 06 03; 26(6):1109-1123. View Abstract

  15. Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning. Radiol Artif Intell. 2024 May; 6(3):e230333. View Abstract

  16. Aberrant DNA repair reveals a vulnerability in histone H3.3-mutant brain tumors. Nucleic Acids Res. 2024 Mar 21; 52(5):2372-2388. View Abstract

  17. Consensus framework for conducting phase I/II clinical trials for children, adolescents, and young adults with pediatric low-grade glioma: Guidelines established by the International Pediatric Low-Grade Glioma Coalition Clinical Trial Working Group. Neuro Oncol. 2024 03 04; 26(3):407-416. View Abstract

  18. Indoximod-based chemo-immunotherapy for pediatric brain tumors: A first-in-children phase I trial. Neuro Oncol. 2024 02 02; 26(2):348-361. View Abstract

  19. Pediatric low-grade glioma: State-of-the-art and ongoing challenges. Neuro Oncol. 2024 01 05; 26(1):25-37. View Abstract

  20. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. Mol Cell. 2024 Jan 18; 84(2):261-276.e18. View Abstract

  21. A Pilot Study Omitting Radiation in the Treatment of Children with Newly Diagnosed Wnt-Activated Medulloblastoma. Clin Cancer Res. 2023 12 15; 29(24):5031-5037. View Abstract

  22. A road map for the treatment of pediatric diffuse midline glioma. Cancer Cell. 2024 01 08; 42(1):1-5. View Abstract

  23. Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. medRxiv. 2023 Nov 22. View Abstract

  24. "LOGGIC" of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas. Neuro Oncol. 2023 11 02; 25(11):2098-2099. View Abstract

  25. ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma. Clin Cancer Res. 2023 07 14; 29(14):2651-2667. View Abstract

  26. Genome-wide pooled CRISPR screening in neurospheres. Nat Protoc. 2023 07; 18(7):2014-2031. View Abstract

  27. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma. bioRxiv. 2023 May 06. View Abstract

  28. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro Oncol. 2023 04 06; 25(4):735-747. View Abstract

  29. Accurate diagnosis of pediatric brain cancers. Nat Med. 2023 04; 29(4):787-788. View Abstract

  30. Author Correction: Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2023 Feb; 614(7948):E40. View Abstract

  31. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023 Feb; 36:100857. View Abstract

  32. Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdac182. View Abstract

  33. K27M in canonical and noncanonical H3 variants occurs in distinct oligodendroglial cell lineages in brain midline gliomas. Nat Genet. 2022 12; 54(12):1865-1880. View Abstract

  34. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2022 12; 177:120-142. View Abstract

  35. Molecular genetics of paediatric brain tumours and opportunities for precision medicine - a focus on infant tumours. Curr Opin Neurol. 2022 12 01; 35(6):772-778. View Abstract

  36. FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. Cancer Res. 2022 09 02; 82(17):2980-3001. View Abstract

  37. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma. Nat Commun. 2022 08 16; 13(1):4814. View Abstract

  38. Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. Neuro Oncol. 2022 08 01; 24(8):1352-1363. View Abstract

  39. Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. Nat Cancer. 2022 08; 3(8):994-1011. View Abstract

  40. Accuracy of central neuro-imaging review of DIPG compared with histopathology in the International DIPG Registry. Neuro Oncol. 2022 05 04; 24(5):821-833. View Abstract

  41. Pediatric pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac056. View Abstract

  42. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022 02 01; 13(1):604. View Abstract

  43. Characteristics of patients =10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022 01 05; 24(1):141-152. View Abstract

  44. The challenges in treating embryonal tumors with multilayered rosettes (ETMR) and other infant brain tumors. Neuro Oncol. 2022 01 05; 24(1):138-140. View Abstract

  45. Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. J Neuropathol Exp Neurol. 2021 11 19; 80(11):1052–1059. View Abstract

  46. A first-generation pediatric cancer dependency map. Nat Genet. 2021 Apr; 53(4):529-538. View Abstract

  47. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 03; 146:115-124. View Abstract

  48. Outcomes after first relapse of childhood intracranial ependymoma. Pediatr Blood Cancer. 2021 08; 68(8):e28930. View Abstract

  49. Advances in the classification and treatment of pediatric brain tumors. Curr Opin Pediatr. 2021 02 01; 33(1):26-32. View Abstract

  50. Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell. 2020 12 10; 183(6):1617-1633.e22. View Abstract

  51. CloneSifter: enrichment of rare clones from heterogeneous cell populations. BMC Biol. 2020 11 24; 18(1):177. View Abstract

  52. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma. J Neurooncol. 2020 Sep; 149(2):253-262. View Abstract

  53. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020 04; 580(7804):517-523. View Abstract

  54. The "Risk" in Pediatric Low-Grade Glioma. Cancer Cell. 2020 04 13; 37(4):424-425. View Abstract

  55. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020 02; 578(7793):102-111. View Abstract

  56. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020 01 13; 37(1):104-122.e12. View Abstract

  57. The Power of Human Cancer Genetics as Revealed by Low-Grade Gliomas. Annu Rev Genet. 2019 12 03; 53:483-503. View Abstract

  58. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019 12; 576(7785):112-120. View Abstract

  59. Increasing value of autopsies in patients with brain tumors in the molecular era. J Neurooncol. 2019 Nov; 145(2):349-355. View Abstract

  60. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019 08 19; 10(1):3731. View Abstract

  61. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 08 05; 21(8):968-980. View Abstract

  62. Towards Immunotherapy for Pediatric Brain Tumors. Trends Immunol. 2019 08; 40(8):748-761. View Abstract

  63. Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. Nat Commun. 2019 06 03; 10(1):2400. View Abstract

  64. Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. Elife. 2019 03 12; 8. View Abstract

  65. Old meet new-the path to combination treatments in pediatric low-grade gliomas. Neuro Oncol. 2019 02 14; 21(2):143-145. View Abstract

  66. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019 02; 31(1):21-27. View Abstract

  67. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling. Cancer Cell. 2018 12 10; 34(6):922-938.e7. View Abstract

  68. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018 10 09; 20(11):1547-1555. View Abstract

  69. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330. View Abstract

  70. Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021. View Abstract

  71. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science. 2018 04 20; 360(6386):331-335. View Abstract

  72. Landscapes of childhood tumours. Nature. 2018 03 15; 555(7696):316-317. View Abstract

  73. SvABA: genome-wide detection of structural variants and indels by local assembly. Genome Res. 2018 04; 28(4):581-591. View Abstract

  74. Landscapes of childhood tumours. Nature. 2018 Mar; 555(7696):316-317. View Abstract

  75. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 2018 01 22; 20(2):160-173. View Abstract

  76. Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. 2018 Apr; 137(2):269-278. View Abstract

  77. Open data: Spot data glitches before publication. Nature. 2017 10 18; 550(7676):333. View Abstract

  78. Brainstem angiocentric gliomas with MYB-QKI rearrangements. Acta Neuropathol. 2017 Oct; 134(4):667-669. View Abstract

  79. Case-based review: pediatric medulloblastoma. Neurooncol Pract. 2017 Sep; 4(3):138-150. View Abstract

  80. Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. J Neurooncol. 2017 Oct; 135(1):201-211. View Abstract

  81. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017 Jul 01; 19(7):986-996. View Abstract

  82. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2017 06 01; 19(6):750-761. View Abstract

  83. Population Control: Cortical Interneurons Modulate Oligodendrogenesis. Neuron. 2017 May 03; 94(3):415-417. View Abstract

  84. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability. Elife. 2017 02 08; 6. View Abstract

  85. Central Versus Extraventricular Neurocytoma in Children: A Clinicopathologic Comparison and Review of the Literature. J Pediatr Hematol Oncol. 2016 08; 38(6):479-85. View Abstract

  86. Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol. 2017 01; 19(1):22-30. View Abstract

  87. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016 06; 128(2):293-302. View Abstract

  88. Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. Cancer. 2016 Apr 15; 122(8):1261-9. View Abstract

  89. Building a new process: Nursing verification of pediatric oral chemotherapy. J Clin Oncol. 2016 Mar; 34(7_suppl):199. View Abstract

  90. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016 Mar; 48(3):273-82. View Abstract

  91. Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol. 2016 Jan; 126(1):165-174. View Abstract

  92. Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. Neuro Oncol. 2015 Nov; 17(11):1486-96. View Abstract

  93. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015 Jan 06; 112(1):232-7. View Abstract

  94. Epigenetic targeting of hedgehog pathway transcriptional output. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii25. View Abstract

  95. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul; 20(7):732-40. View Abstract

  96. Pediatric low-grade gliomas: how modern biology reshapes the clinical field. Biochim Biophys Acta. 2014 Apr; 1845(2):294-307. View Abstract

  97. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database. Pediatr Blood Cancer. 2014 Jul; 61(7):1173-9. View Abstract

  98. The oncogenic properties of EWS/WT1 of desmoplastic small round cell tumors are unmasked by loss of p53 in murine embryonic fibroblasts. BMC Cancer. 2013 Dec 09; 13:585. View Abstract

  99. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014 Feb 15; 20(4):912-25. View Abstract

  100. Morning glory disc anomaly in association with ipsilateral optic nerve glioma. Arch Ophthalmol. 2012 Aug; 130(8):1082-3. View Abstract

  101. ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1055-61. View Abstract

  102. The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases. Pathology. 2011 Jan; 43(1):9-16. View Abstract

  103. Rhabdoid tumour: a malignancy of early childhood with variable primary site, histology and clinical behaviour. Pathology. 2008 Dec; 40(7):664-70. View Abstract

  104. Arousal responses and risk factors for sudden infant death syndrome. Sleep Med. 2002 Dec; 3 Suppl 2:S61-5. View Abstract

  105. Effects of age and sleeping position on arousal from sleep in preterm infants. Sleep. 2002 Nov 01; 25(7):746-50. View Abstract

  106. Temperament ratings do not predict arousability in normal infants and infants at increased risk of sudden infant death syndrome. J Dev Behav Pediatr. 2002 Oct; 23(5):365-70. View Abstract
BESbswy